nach oben

International Journal of Clinical Oncology

Erschienen in:

01.02.2019 | Original Article

Gestational trophoblastic neoplasia with brain metastasis at initial presentation: a retrospective study

verfasst von: Déborah Gavanier, Hélène Leport, Jérome Massardier, Fatima Abbas, Anne-Marie Schott, Touria Hajri, François Golfier, Pierre-Adrien Bolze

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate the survival and functional outcome of patients with brain metastasis due to gestational trophoblastic neoplasia (GTN).

Methods

A 17-year retrospective study based on case review of women with brain metastasis from GTN identified by the electronic databases held in the French Reference Centre. Primary outcome measure: 5-year overall survival calculated with the Kaplan–Meier method. Secondary outcome measures: causes of death, prognostic factors and functional outcomes.

Results

21 patients had GTN brain metastasis and were treated with multidrug chemotherapy without concomitant whole-brain radiation therapy. Three patients died early (< 4 weeks) of cerebral hemorrhage, 3 died ≥ 1 months after treatment initiation and 15 were alive at the date of last contact. The overall survival rate at 5 years was 69.8% (95% CI 44.3–85.3). After excluding early deaths, the survival rate at 5 years was 81.5% (95% CI 52.3–93.7). No predictive factor of survival was identified. Although 11 of the 12 (92%) surviving patients contacted still reported sequelae, nine of them (75%) had resumed a normal life.

Conclusions

After excluding early deaths, this study implies a high survival rate in patients with brain metastasis from GTN. These results were achieved in the total absence of whole-brain radiotherapy and almost completely without the need for intrathecal methotrexate.

Piura E, Piura B (2014) Brain metastases from gestational trophoblastic neoplasia: review of pertinent literature. Eur J Gynaecol Oncol 35:359–367PubMed

Lurain JR (2010) Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol 203:531–539. https://doi.org/10.1016/j.ajog.2010.06.073 CrossRefPubMed

Savage P, Kelpanides I, Tuthill M et al (2015) Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome. Gynecol Oncol 137:73–76. https://doi.org/10.1016/j.ygyno.2015.01.530 CrossRefPubMed

Evans AC, Soper JT, Clarke-Pearson DL et al (1995) Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol 59:226–230CrossRefPubMed

Bolze P-A, Riedl C, Massardier J et al (2016) Mortality rate of gestational trophoblastic neoplasia with a FIGO score of ≥ 13. Am J Obstet Gynecol 214:390.e1–390.e8. https://doi.org/10.1016/j.ajog.2015.09.083 CrossRef

Newlands ES, Holden L, Seckl MJ et al (2002) Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J Reprod Med 47:465–471PubMed

Lurain JR (2011) Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol 204:11–18. https://doi.org/10.1016/j.ajog.2010.06.072 CrossRefPubMed

Ngan HYS, Seckl MJ, Berkowitz RS et al (2015) Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet 131 Suppl 2:S123–S126. https://doi.org/10.1016/j.ijgo.2015.06.008

Maladies trophoblastiques gestationnelles, collection Recommandations et référentiels, ouvrage collectif édité par l’Inca, Boulogne-Billancourt, septembre 2010. http://www.e-cancer.fr/content/download/58366/532104/file/Plaquette_MTG-02-09-10.pdf

10.

Alifrangis C, Agarwal R, Short D et al (2013) EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 31:280–286. https://doi.org/10.1200/JCO.2012.43.1817 CrossRefPubMed

11.

Xiao C, Yang J, Zhao J et al (2015) Management and prognosis of patients with brain metastasis from gestational trophoblastic neoplasia: a 24-year experience in Peking union medical college hospital. BMC Cancer 15:318. https://doi.org/10.1186/s12885-015-1325-7 CrossRefPubMedPubMedCentral

12.

Bolze P-A, Attia J, Massardier J et al (2015) Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. Eur J Cancer 51:1725–1731. https://doi.org/10.1016/j.ejca.2015.05.026 CrossRefPubMed

13.

Seckl MJ, Sebire NJ, Berkowitz RS (2010) Gestational trophoblastic disease. Lancet 376:717–729CrossRefPubMed

14.

Neubauer NL, Strohl AE, Schink JC, Lurain JR (2015) Fatal gestational trophoblastic neoplasia: An analysis of treatment failures at the Brewer Trophoblastic Disease Center from 1979 to 2012 compared to 1962–1978. Gynecol Oncol. https://doi.org/10.1016/j.ygyno.2015.05.041 CrossRefPubMed

15.

Berkowitz RS, Goldstein DP, Bernstein MR (1984) Choriocarcinoma following term gestation. Gynecol Oncol 17:52–57CrossRefPubMed

16.

Deng L, Zhang J, Wu T, Lawrie TA (2013) Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005196.pub4 CrossRefPubMed

17.

Rustin GJ, Newlands ES, Begent RH et al (1989) Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 7:900–903CrossRefPubMed

18.

Small W, Lurain JR, Shetty RM et al (1996) Gestational trophoblastic disease metastatic to the brain. Radiology 200:277–280. https://doi.org/10.1148/radiology.200.1.8657926 CrossRefPubMed

19.

Neubauer NL, Latif N, Kalakota K et al (2012) Brain metastasis in gestational trophoblastic neoplasia: an update. J Reprod Med 57:288–292PubMed

20.

Altintaş A, Vardar MA (2001) Central nervous system involvement in gestational trophoblastic neoplasia. Eur J Gynaecol Oncol 22:154–156PubMed

21.

Tetef ML, Margolin KA, Doroshow JH et al (2000) Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol 46:19–26CrossRefPubMed

22.

Howard SC, Jones DP, Pui C-H (2011) The tumor lysis syndrome. N Engl J Med 364:1844–1854. https://doi.org/10.1056/NEJMra0904569 CrossRefPubMedPubMedCentral

23.

Schuman S, Pearson JM, Lucci JA, Twiggs LB (2010) Metastatic gestational trophoblastic neoplasia complicated by tumor lysis syndrome, heart failure, and thyrotoxicosis: a case report. J Reprod Med 55:441–444PubMed

24.

Crawford RA, Newlands E, Rustin GJ et al (1997) Gestational trophoblastic disease with liver metastases: the Charing Cross experience. Br J Obstet Gynaecol 104:105–109CrossRefPubMed

25.

Athanassiou A, Begent RH, Newlands ES et al (1983) Central nervous system metastases of choriocarcinoma. 23 years’ experience at Charing Cross Hospital. Cancer 52:1728–1735CrossRefPubMed

Titel: Gestational trophoblastic neoplasia with brain metastasis at initial presentation: a retrospective study
verfasst von: Déborah Gavanier
Hélène Leport
Jérome Massardier
Fatima Abbas
Anne-Marie Schott
Touria Hajri
François Golfier
Pierre-Adrien Bolze
Publikationsdatum: 01.02.2019
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2019
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1337-9

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Gestational trophoblastic neoplasia with brain metastasis at initial presentation: a retrospective study